PDCD1 and renal cell adenocarcinoma: The fully human anti–PD-1 mAb BMS-936558/MDX-1106/ONO-4538 (nivolumab), tested in renal cell cancer (RCC), MEL, CRPC, non–small cell lung cancer (NSCLC), and colorectal cancer (CRC), has demonstrated antitumor activity in phase 1/1b studies 11.